According to a new report published by K D Market Insights, titled, “Immunoglobulin Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global immunoglobulin market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The increasing prevalence of immunological and neurological diseases, driving the demand for immunoglobulin therapies. Additionally, advancements in technology and improved immunoglobulin production techniques have enhanced the efficacy of treatments, which are the major factors augmenting the growth of the global immunoglobulin market.

The rising prevalence of key immunodeficiency disorders, such as leukemia, hepatitis, multiple myeloma, and others, has created a significant demand for effective treatment options like immunoglobulin. Are further expected to create ample growth opportunities for the global immunoglobulin market during the forecast period i.e., 2023-2032. Moreover, increasing adoption of immunoglobulin therapy has propelled market expansion. Growing research and development activities in the field of immunoglobulin, is expected to contribute towards the market growth during the period.

The North America region accounted for the largest share in the global immunoglobulin market in 2022. The region is further projected to continue dominating in the market and also register the highest CAGR in the market during the forecast period. This can be attributed to the increasing prevalence of immunodeficiency disorders, favorable reimbursement policies, and robust healthcare infrastructure.

According to mode of delivery, the intravenous segment accounted for the largest market share in the immunoglobulin market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.

The global immunoglobulin market is segmented into product type, application, mode of delivery and region. Based on product type, the market is bifurcated into IgG, IgA, IgM, IgE, and IgD. Based on application, it is classified into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency disease, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. Based on mode of delivery, it is classified into intravenous and subcutaneous.

The global immunoglobulin market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).

Key Insights of Immunoglobulin Market

  • On the basis mode of delivery, the intravenous segment accounted for the largest market share in the immunoglobulin market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
  • On the basis of region, North America accounted for the largest share in the global immunoglobulin market in 2022. The region is further projected to continue dominating in the market during the forecast period.
  • On the basis of region, Asia-Pacific is estimated to account for the second largest share in the market during the forecast period.

Some of the major immunoglobulin companies profiled in the report include Biotest AG, Kedrion Biopharma Inc., Octapharma AG, Bayer AG, China Biologic Products, Inc., LFB SA (LFB Biotechnologies SAS), Baxter International Inc., Grifols S.A., CSL Limited, Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Shanghai RAAS, and China Biologic Products Holdings, Inc. (Taibang Biologic Group).

Related Reports :-

https://www.kdmarketinsights.com/reports/sinusitis-treatment-market/7121

https://www.kdmarketinsights.com/reports/urea-cycle-disorder-treatment-market/7120

https://www.kdmarketinsights.com/reports/vertigo-treatment-market-1/7119

https://www.kdmarketinsights.com/reports/fusion-inhibitors-market/7117